Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

DNA-Guided heart drug choice may save lives in coronary artery disease

NCT ID NCT06665919

Disease control Sponsor: Vistamedi Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether using a person's genetic information to choose their blood-thinning medication (clopidogrel or an alternative) leads to better outcomes after a heart procedure. 283 adults with chronic coronary artery disease who had a stent placed were split into two groups: one received standard care, and the other had their treatment guided by a genetic test. The goal was to see if the genetic approach reduced deaths, heart attacks, and other heart-related events in real-world practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

283 people

The number who actually took part.

Started

Jun 2023

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed with chronic coronary artery disease; * Undergone elective PCI within the last 12 weeks without procedure-related complications; * LVEF≥38% after index PCI; * Completed informed consent form for participation in the study; Exclusion Criteria: * Concomitant using of potent CYP3A4 or CYP2C19 inhibitors; * Morbid obesity, BMI 40 kg/sq.m or more; * Type 1 diabetes mellitus; * Poorly controlled type 2 diabetes mellitus, HbA1c - 9% or more; * Acute Myocardium Infarction; * Coronary artery bypass grafting performed within the last 12 weeks; * Valvular heart disease due to dysplasia, connective tissue disorders or inflammatory disorders, or valvular disorders requiring cardiac surgery; * History of severe hepatic impairment; * Severe chronic kidney disease; * Clinically important leucopenia, lymphopenia, thrombocytopenia or thrombocytosis; * History of hemorrhagic diathesis or coagulopathy; * An active or an obvious threat of bleeding (including GI bleeding): * Bleeding within the past 6 months that required hospitalization; * Blood transfusion during the past 6 months or its refusal; * History of intracranial hemorrhage; * Cardiac or non-cardiac degenerative disease, including: cardiomyopathy, restrictive lung disease, or Neurodegenerative diseases; * Malignant tumor (cancer) that limits life expectancy to less than one year; * Current chemotherapy or immunosuppressive therapy; * Ongoing immunosuppression or immunosuppressive conditions; * Pregnancy or lactation period; * Any disease/condition control of which is not achieved; * Personal (patient/physician dependent) or health care system-related circumstances that can restrict or limit any study procedures or operations.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adverse cardiac events are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiovascular disorder coronary artery disorder coronary thrombosis Death Hemorrhage hemorrhagic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adverse cardiac events Bleeding Clopidogrel resistance Coronary artery disease Coronary thrombosis Death Death from cardiovascular disease Hospitalisations

Contacts and locations

Locations

  • 1st University Clinic of the Tbilisi State Medical University

    Tbilisi, Georgia

  • Cardio Expert Ltd., Clinic Cardio

    Tbilisi, Georgia

  • T. Oragvelidze Cardiology Center

    Tbilisi, Georgia

  • Tbilisi Institute of Medicine

    Tbilisi, Georgia

More trials for these conditions

Other studies related to the condition(s) this trial covers.